All In Biotech

Drug Trial Radar · NCT04819464

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

An Open-label, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cenerimod After Single-dose Administration in Subjects With Hepatic Impairment and in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 25, 2021

Primary completion

Aug 18, 2024

Study completion Aug 18, 2024

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single-dose, phase 1 study, to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of cenerimod (ACT-334441).

Conditions

  • Healthy
  • Hepatic Impairment

Interventions

  • CenerimodDrug

    A single oral dose of 0.5 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curves (AUC0-t): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
  2. Area under the plasma concentration-time curve from zero to infinity (AUC0-inf): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
  3. Maximum plasma concentration (Cmax): cenerimod.Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
  4. Time to reach Cmax (tmax): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
  5. Terminal half-life (t½): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
  6. Plasma protein binding of cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
  7. Apparent clearance (CL/F) of cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
  8. Apparent volume of distribution (Vz/F) of cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • CRU Hungary

    Kistarcsa, Hungary

  • BlueClinical Phase 1 Hospital de Prelado

    Porto, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.